Oxford Biomedica - Vector innovation key to cell and gene evolution
Oxford Biomedica (OXB) is a pioneer and global leader in the development and manufacture of commercial-scale lentiviral vectors (LVVs), a critical...
320 Views
Oxford Biomedica - COVID-19 vaccine collaboration agreement
Oxford Biomedica (OXB) has signed a five-year collaboration agreement with the Vaccines Manufacturing and Innovation Centre (VMIC), a non-profit...
238 Views
Oxford Biomedica - Further deals anticipated in 2020
Oxford Biomedica’s (OXB) FY19 results highlight strong operational momentum despite capacity constraints. OXB is investing for future growth and...
134 Views
Oxford Biomedica - Juno deal expands CAR-T revenue streams
Following the 2017 commercial launch of partner Novartis’s Kymriah (a CD19-targeting CAR-T that is approved for pALL and DLBCL), Oxford Biomedica...
619 Views
Oxford Biomedica - OxBox investment to aid future growth
Oxford Biomedica (OXB) is a pioneer and global leader in the development and manufacture of commercial-scale lentiviral vectors (LVV), a critical...
768 Views